Innovating Works

PARSEQ LAB

Desconocido
LungCARD: Blood test for clinical therapy guidance of non small cell lung cancer patients PARSEQ LAB CO LTD participó en un H2020: H2020-MSCA-RISE-2016 Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSC...
2016-12-02 - 2022-10-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.